Cardiometabolic & kidneyCohort study
Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study
- Retrospective cohort study
- multicentre
- propensity-score matched
Authors' conclusion
Use of SGLT2is in patients with T2DM and concomitant AF was associated with reduced mortality or HF hospitalization events.
Study context
- Population
- Patients with atrial fibrillation (AF) and T2DM, electronic medical records of seven medical centres1:2 propensity score (PS)-matched
- Participants
- 11,012 patients
- Exposure
- SGLT2i use vs no SGLT2i use
- SGLT2in = 1,115
- Controln = 2,050reference
- Outcome
- Composite of:
- All-cause death
- HF hospitalization
- Follow-up
- 3 years
Main finding
As reported in the abstract
Hazard ratio
0.69
95% CI 0.55–0.87
By group
SGLT2i vs Control
HR 0.69 (95% CI 0.55–0.87)
Observational data: associations, not effects.
Further findings
All-cause mortality
- SGLT2i use associated with significantly lower all-cause mortality (95% CI 0.29-0.67)
- HR 0.43
- PS-matched
Heart failure (HF) hospitalization
- SGLT2i use associated with significantly lower HF hospitalization (95% CI 0.59-0.99)
- HR 0.77
- PS-matched
Safety
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Adverse renal events (>50% increase in serum creatinine or initiation of dialysis) | 0.50 (0.38–0.66) | P < 0.001 | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study. Eur J Prev Cardiol. Published 5 October 2023. doi:10.1093/eurjpc/zwad322
Summarised from the published abstract; every number is checked against it